Research & Development
Invitae announces data on epilepsy genetic testing outcomes
Among patients whose treatment was changed based on genetic testing, 75% reported positive health outcomes, including 65% who saw a reduction in frequency -- even elimination -- of seizures.
November 1, 2022
Variantyx obtains $20M in funding
Whole genome sequencing tracks changes in genes that can cause disease. Variantyx is developing the testing method for the diagnosis of rare inherited and neurological disorders, it said.
March 15, 2021
Researchers outline neurological signs of COVID-19
The neurological complications of COVID-19 are becoming more obvious as the pandemic wears on, and they consist of a startling range of conditions, according to a team led by Ross Paterson, PhD, of University College London.
July 8, 2020
Real-world study: Genetic testing appears underused in autism
Neurological medicine researchers evaluated how frequently chromosomal microarray (CMA) and fragile X syndrome testing were conducted in people with autism spectrum disorder through the Rhode Island Consortium for Autism Research and Treatment (RI-CART). Results were reported by Dr. Eric Morrow, PhD, head of the Developmental Disorders Genetics Research Program at Brown University, and colleagues in a research letter.
May 13, 2020
Pathology study challenges conventional wisdom on brain injury
The prospective Traumatic Head Injury Neuroimaging Classification (THINC) study was funded by the U.S. Department of Defense and the National Institute of Neurological Disorders and Stroke (NINDS).
October 14, 2019
FYR gets NIH small business grant for epilepsy diagnostics
The grant was awarded by the NIH's National Institute of Neurological Disorders and Stroke, through the government's Small Business Innovation Research program. In the first phase of the funding, FYR Diagnostics will develop biomarkers for use in diagnostic kits.
October 9, 2019
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
Invitae offers 4 more no-charge genetic tests
These four conditions were chosen because testing is underutilized, so there is room to improve diagnosis and treatment, the company explained in a statement. Patients who meet eligibility criteria can access Invitae's company- and organization-sponsored testing programs by enrolling through their doctors. The sponsors get deidentified information and contact information from participating clinicians.
July 23, 2019
Intensive blood sugar control has low value in acute stroke
The trial -- dubbed the Stroke Hyperglycemia Insulin Network Effort (SHINE) -- compared intensive and standard blood glucose control using insulin in 1,151 acute stroke patients and showed good outcomes for 20% in both cohorts, Dr. Karen Johnston, chair of neurology at the University of Virginia, and colleagues reported (JAMA, July 23/30, 2019, Vol. 322:4, pp. 326-335).
July 23, 2019
Cerebrospinal fluid test helps pinpoint dementia disorders
The meta-analysis of studies involving about 10,000 people with neurological disorders showed that neurofilament light protein as measured with a commercially available immunoassay was elevated for people with neurological and psychiatric conditions. Results were broadly similar; however, frontotemporal dementia and HIV-related cognitive decline were differentiated from other dementias, and Parkinson's disease was differentiated from atypical parkinsonian conditions.
June 17, 2019
Page 1 of 1